ClinicalTrials.gg
Active, not recruitingNCT04801771Updated Aug 25, 2026

Effects of Hypoglossal Nerve Stimulation on Cognition and Language in Down Syndrome and Obstructive Sleep Apnea

An interventional study of Inspire Upper Airway Stimulation (UAS) System in Down Syndrome and Obstructive Sleep Apnea, sponsored by Inspire Medical Systems, Inc.. Active, not recruiting at 8 sites in United States. Open to participants aged 10 Years to 21 Years. Per ClinicalTrials.gov, last updated 2026-08-25.

Sponsored by Inspire Medical Systems, Inc. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
57
Allocation
Not applicable
Ages
10 Years to 21 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 205 studies in Down Syndrome with a site in United States — 47 open to participants now, 55 under way, 4 of them phase 3. Down Syndrome · United States.

Enrollment
47th of 131
57 · median 40
Started
2021
with 15 others
No phase
82 of 205
19 open now
Primary completion
2026-07
later than 5 of 54 live
Registered
136th of 205
by date

Among the 205 studies in Down Syndrome with a site in United States, this one is the 47th largest by enrollment of the 131 interventional ones that give a count, is one of 16 that started in 2021, is one of 82 with no phase, reaches primary completion later than 5 of the 54 other live ones, and was the 136th registered.

Down Syndrome

439 studies on the registry are indexed under Down Syndrome; 99 are open to participants now.

Browse Down Syndrome studies →

Open to participants now

47 of the 205 studies in Down Syndrome with a site in United States are open now. Recruiting first, the newest first:

42 more — sign in →

All 47 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 74 Down Syndrome studies recruiting now, 14 (19%) set no upper age limit and 57 (77%) stop at 75 or younger; 60 take children under 18; 19 take healthy volunteers.

This study: 10 Years to 21 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 205 studies in Down Syndrome with a site in United States, or all of them as a file.
02

Study summary

This study is a prospective, single-arm study conducted under a common implant and follow-up protocol. The objective will be to follow fifty-seven (57) adolescents and young adults (10-21 years of age), with Down syndrome, moderate to severe sleep apnea, and post-adenotonsillectomy, for 12 months after undergoing implant of the Inspire Upper Airway Stimulation (UAS) System. The study is being conducted in order to evaluate objective change in cognition and expressive language after implant and therapy with the Inspire UAS System.

Read the detailed description

This study is a prospective, single-arm study conducted under a common implant and follow-up protocol. The objective will be to follow fifty-seven (57) adolescents and young adults (10-21 years of age), with Down syndrome, moderate to severe sleep apnea, and post-adenotonsillectomy, for 12 months after undergoing implant of the Inspire Upper Airway Stimulation (UAS) System. The study is being conducted in order to evaluate objective change in cognition and expressive language after implant and therapy with the Inspire UAS System.

Prior to implant subjects will be required to meet eligibility criteria, complete quality of life questionnaires and undergo neurocognitive testing (NCT) and expressive language sampling. Eligibility criteria will be determined via review of medical records, an in-lab polysomnography (sleep study), and a drug-induced sleep endoscopy (DISE).

After implant of the Inspire UAS System, subjects will undergo five (5) study visits. Four (4) of the visits will include an in-lab sleep study (PSG). Follow-up expressive language sampling and neurocognitive testing will be performed at 6 months post-implant. Follow-up quality of life questionnaires will be completed at 12 months post-implant.

Subjects will conclude their participation in the study at the end of their 12 month study visit.

03

Conditions studied

  • Down Syndrome
  • Obstructive Sleep Apnea

Keywords

  • Hypoglossal nerve stimulation
04

Who can participate

Ages eligible
10 Years to 21 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of Down syndrome
  • Age 10-21 years
  • Prior adenotonsillectomy
  • Severe OSA (AHI > 10, AHI \< 50, no more than 25% AHI attributable to central events) based on prior in-lab PSG performed after adenotonsillectomy and within 18 months of enrollment
  • Approval from at least two of the three physician reviewers based upon the results of a routine drug-induced sleep endoscopy (DISE) having occurred within 12 months of enrollment
  • Subjects must have either tracheotomy or be ineffectively treated with CPAP due to non-compliance, discomfort, un-desirable side effects, persistent symptoms despite compliance use, or refusal to use the device
  • Children and their parents/guardians must be willing to have stimulation hardware permanently implanted, and be willing to participate in follow-up visits, postoperative PSG, and questionnaire completion
  • Children's parents/guardians must complete a questionnaire confirming that their child is capable of communicating feelings of pain or discomfort. They must also confirm they are able to assess their child for adverse effects related to device implantation
  • Children and their parents/guardians must be proficient in English

Exclusion criteria

Exclusion Criteria:

  • (BMI) above the 95th percentile for subject's age
  • Circumferential airway collapse at the level of the velopharynx observed during DISE
  • Other medical conditions resulting in medical instability (eg. congestive heart failure, recent open heart surgery, , or chronic lung disease or aspiration)
  • Presence of another medical condition requiring future magnetic resonance imaging (MRI) of the chest
  • Patients with another implantable device which could interact unintentionally with the Inspire system
  • Any for general anesthesia
  • History of bleeding or clotting disorders and those on blood thinning or NSAID medications for the week prior to implantation surgery. Subjects will be asked to refrain from the use of NSAIDS for two weeks after implantation or any revision surgeries
  • Subject is currently taking muscle relaxant medication
  • less than 12 months
  • Subject's inability to communicate pain or discomfort to their caretaker/parent, based on parental or investigator assessment
  • Nonverbal candidates will be excluded due to an inability to complete testing procedures including expressive language sampling
  • Subjects with a co-occurring diagnosis of autism spectrum disorder
  • Subjects that have a positive β-HCG
  • Subjects deemed unfit for participation by the investigator for any other reason
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
57 participants (actual)

Study arms

  • Experimental
    Subjects implanted with Inspire UAS System

    Subjects who meet eligibility criteria will be implanted with the Inspire Upper Airway Stimulation (UAS) System.

    Device: Inspire Upper Airway Stimulation (UAS) System

Interventions

  • DeviceInspire Upper Airway Stimulation (UAS) System

    The Inspire UAS System is an implantable device that provides hypoglossal nerve stimulation for the treatment of obstructive sleep apnea.

    Also known as: Hypoglossal nerve stimulation

06

What researchers measure

Primary outcomes

  1. Change in intelligence using the Kaufman Brief Intelligence Scale (KBIT-2)

    Change in the Intelligence Quotient Standard Score of at least 0.5 standard deviation from baseline

    Time frame: 6 Months post-implant

  2. Change in attention using the Wechsler Intelligence Scale

    Change in Cancellation scaled score of at least 0.5 standard deviation from baseline

    Time frame: 6 Months post-implant

  3. Change in processing speed using the Cambridge Neuropsychological Test Automated Battery (CANTAB)

    Change in RTIFMDRT and RTIFMDMT raw scores of at least 0.5 standard deviation from baseline

    Time frame: 6 Months post-implant

  4. Change in executive functioning using the Delis-Kaplan Executive Functioning System (DKEFS)

    Change in Category Functioning scaled score of at least 0.5 standard deviation from baseline

    Time frame: 6 Months post-implant

  5. Change in learning and memory using the Cambridge Neuropsychological Test Automated Battery - Paired Associates Learning

    Change in PAL-TEA raw score of at least 0.5 standard deviation from baseline

    Time frame: 6 Months post-implant

  6. Change in language using Expressive Language Sampling

    Change in % of unintelligible C-units, number of different word roots and mean length of C-units in morphemes of at least 0.5 standard deviation from baseline

    Time frame: 6 Months post-implant

Secondary outcomes

  1. Rate of procedure and device-related adverse events

    Procedure and device-related adverse events will be collected in order to profile the safety of hypoglossal nerve stimulation in adolescents. Number and percent of procedure and device-related adverse events will be reported

    Time frame: Implant through 12 Months post-implant

  2. Change in Obstructive Sleep Apnea (OSA)

    Change in sleep apnea will be measured using standard in-lab PSG measures including oxygen level, partial and complete airway obstruction, and arousals. Improvement will be defined as a 50% or more decrease in AHI.

    Time frame: 3, 6, 12 Months post-implant

  3. Change in quality of life as measured by OSA-18 and ESS-CHAD questionnaires

    Quality of life improvements will be measured using the OSA-18 and ESS-CHAD. Mean scores for each questionnaire will be reported at baseline and 12 months post-implant.

    Time frame: 12 months post-implant

07

Study locations

8 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in Jul 2026, 60 months.

Of 165 interventional studies with no phase under Down Syndrome, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 35. This study's 60 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2020
First posted
Mar 17, 2021
StartActual
Jun 24, 2021
Primary completionActual
Jul 1, 2026
CompletionEst.
Sep 30, 2026
Last update
Aug 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04801771
Lead sponsor
Inspire Medical Systems, Inc.
Responsible party
Sponsor
First posted
Mar 17, 2021
Start date
Jun 24, 2021
Primary completion
Jul 1, 2026
Completion
Sep 30, 2026 (estimated)
Last update
Aug 25, 2026

Study contacts

Christopher Hartnick, MD
principal investigator · The Massachusetts Eye and Ear Infirmary

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion